Research & Development News Channel

First-in-human clinical trial for a vaccine to treat opioid use disorders enrolls first patients

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by researchers at the University of Minnesota Medical School.

Funded by a grant from the National Institutes of Health, the trial will test the safety and potential efficacy of a vaccine that is designed to selectively prevent the euphoric and toxic effects of oxycodone.

No serious health effects linked to mRNA COVID-19 vaccines

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 vaccines.

The study published September 2 in JAMA reports the first comprehensive findings of the Vaccine Safety Datalink (VSD), which studies patient records for 12 million people in 5 Kaiser Permanente service regions along with HealthPartners in Minneapolis, the Marshfield Clinic in Wisconsin, and Denver Health.

Blood vessels produce growth factor that promotes metastases

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a distant organ is promoted by factors whose production is induced by the primary tumor itself. Scientists from the German Cancer Research Center (DKFZ) and the Medical Faculty Mannheim, Heidelberg University, have now identified a new growth factor produced by blood vessels that enables tumor cells to metastatically colonize organs.

Rheumatoid arthritis treated with implanted cells that release drug

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically engineered cells that, when implanted in mice, will deliver a biologic drug in response to inflammation.

A drug costing less than €2 a day helps in the treatment of severely ill COVID-19 patients

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published today in the Journal of the American College of Cardiology (JACC).

New study examines 'Achilles heel' of cancer tumours

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cancer cells rely on to adapt and survive when oxygen levels are low.

The findings, published today in Science Advances, will help researchers develop new treatment strategies to limit the progression of solid cancer tumours, which represent the majority of tumour types that arise in the body.

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend millions of dollars to determine a molecular structure - and even such massive efforts are frequently unsuccessful.

Research & Development News

First-in-human clinical trial for a vaccine to treat opioid use disorders enrolls first patients

No serious health effects linked to mRNA COVID-19 vaccines

Blood vessels produce growth factor that promotes metastases

Rheumatoid arthritis treated with implanted cells that release drug

A drug costing less than €2 a day helps in the treatment of severely ill COVID-19 patients

New study examines 'Achilles heel' of cancer tumours

AI algorithm solves structural biology challenges

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs